Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction

Cancer Science

Volumn 103, Issue 1, 2012, Pages 7-16

  Bae, Jae Ho ^a   Kim, So Jung ^a   Kim, Mi Ju ^a   Oh, Sae Ock ^a   Chung, Joo Seop ^a   Kim, Sun Hee ^a   Kang, Chi Dug ^a  

^a Pusan National University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; BAY 11 7092; ERLOTINIB; GEFITINIB; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NATURAL KILLER CELL RECEPTOR NKG2D; PHOSPHATIDYLINOSITOL 3 KINASE; TRANSCRIPTION FACTOR AP 2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER SUSCEPTIBILITY; COLON CANCER; CONTROLLED STUDY; CYTOLYSIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

BLOTTING, WESTERN; CHROMATIN IMMUNOPRECIPITATION; COLONIC NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; GPI-LINKED PROTEINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KILLER CELLS, NATURAL; PROTEIN KINASE INHIBITORS; QUINAZOLINES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84855496189     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02109.x     Document Type: Article

References (59)

1. Bingham S, Riboli E. Diet and cancer - the European prospective investigation into cancer and nutrition. Nat Rev Cancer 2004; 4: 206-15.
2. Sung JJ, Lau JY, Goh KL et al. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol 2005; 6: 871-6.
3. Schmitt C, Ghazi B, Bensussan A. NK cells and surveillance in humans. Reprod Biomed Online 2008; 16: 192-201.
4. Lanier LL. NK cell recognition. Annu Rev Immunol 2005; 23: 225-74.
5. Ljunggren HG, Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990; 11: 237-44.
6. Karre K. Natural killer cell recognition of missing self. Nat Immunol 2008; 9: 477-80.
7. Bauer S, Groh V, Wu J et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727-9.
8. Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev 2010; 235: 267-85.
9. Groh V, Rhinehart R, Randolph-Habecker J et al. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2001; 2: 255-60.
10. Vivier E, Tomasello E, Paul P. Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition? Curr Opin Immunol 2002; 14: 306-11.
11. Watzl C. The NKG2D receptor and its ligands-recognition beyond the "missing self"? Microbes Infect 2003; 5: 31-7.
12. Gasser S, Orsulic S, Brown EJ et al. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005; 436: 1186-90.
13. Armeanu S, Bitzer M, Lauer UM et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005; 65: 6321-9.
14. Skov S, Pedersen MT, Andresen L et al. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 2005; 65: 11136-45.
15. Butler JE, Moore MB, Presnell SR et al. Proteasome regulation of ULBP1 transcription. J Immunol 2009; 182: 6600-9.
16. Lopez-Soto A, Folgueras AR, Seto E et al. HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer. Oncogene 2009; 28: 2370-82.
17. Kim JY, Bae JH, Lee SH et al. Induction of NKG2D ligands and subsequent enhancement of NK Cell-mediated lysis of cancer cells by arsenic trioxide. J Immunother 2008; 31: 475-86.
18. Kim JY, Son YO, Park SW et al. Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation. Exp Mol Med 2006; 38: 474-84.
19. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004; 100: 228-37.
20. Hidalgo M, Villalona-Calero MA, Eckhardt SG et al. Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. J Clin Oncol 2000; 18: 167-77.
21. Barabas K, Milner R, Lurie D et al. Cisplatin: a review of toxicities and therapeutic applications. Vet Comp Oncol 2008; 6: 1-18.
22. Ranson M, Hammond LA, Ferry D et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002; 20: 2240-50.
23. Kurtin SE. Targeting the epidermal growth factor receptor in colorectal carcinoma. Cancer Nurs 2007; 30: S1-9.
24. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37(Suppl 4): S9-15.
25. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-37.
26. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004; 11: 689-708.
27. Von Pawel J. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors. Bull Cancer 2004; 91: E70-6.
28. Yang JL, Qu XJ, Russell PJ et al. Interferon-alpha promotes the anti-proliferative effect of Erlotinib (OSI-774) on human colon cancer cell lines. Cancer Lett 2005; 225: 61-74.
29. Bae JH, Kim JY, Kim MJ et al. Quercetin enhances susceptibility to NK cell-mediated lysis of tumor cells through induction of NKG2D ligands and suppression of HSP70. J Immunother 2010; 33: 391-401.
30. Park SW, Bae JH, Kim SD et al. Comparison of level of NKG2D ligands between normal and tumor tissue using multiplex RT-PCR. Cancer Invest 2007; 25: 299-307.
31. Lopez-Soto A, Quinones-Lombrana A, Lopez-Arbesu R et al. Transcriptional regulation of ULBP1, a human ligand of the NKG2D receptor. J Biol Chem 2006; 281: 30419-30.
32. Gadgeel SM, Ali S, Philip PA et al. Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines. Cancer 2009; 115: 2165-76.
33. Zhang X, Chang A. Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int J Med Sci 2008; 5: 209-17.
34. Groh V, Bahram S, Bauer S et al. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 1996; 93: 12445-50.
35. Borchers MT, Harris NL, Wesselkamper SC et al. NKG2D ligands are expressed on stressed human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2006; 291: L222-31.
36. Venkataraman GM, Suciu D, Groh V et al. Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D. J Immunol 2007; 178: 961-9.
37. Rodriguez-Rodero S, Gonzalez S, Rodrigo L et al. Transcriptional regulation of MICA and MICB: a novel polymorphism in MICB promoter alters transcriptional regulation by Sp1. Eur J Immunol 2007; 37: 1938-53.
38. Gonzalez S, Lopez-Soto A, Suarez-Alvarez B et al. NKG2D ligands: key targets of the immune response. Trends Immunol 2008; 29: 397-403.
39. Xu K, Shu HK. EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas. Cancer Res 2007; 67: 6121-9.
40. Chupreta S, Du M, Todisco A et al. EGF stimulates gastrin promoter through activation of Sp1 kinase activity. Am J Physiol Cell Physiol 2000; 278: C697-708.
41. Lee SR, Park JH, Park EK et al. Akt-induced promotion of cell-cycle progression at G2/M phase involves upregulation of NF-Y binding activity in PC12 cells. J Cell Physiol 2005; 205: 270-7.
42. Alabert C, Rogers L, Kahn L et al. Cell type-dependent control of NF-Y activity by TGF-beta. Oncogene 2006; 25: 3387-96.
43. Lecona E, Barrasa JI, Olmo N et al. Upregulation of annexin A1 expression by butyrate in human colon adenocarcinoma cells: role of p53, NF-Y, and p38 mitogen-activated protein kinase. Mol Cell Biol 2008; 28: 4665-74.
44. Molinero LL, Domaica CI, Fuertes MB et al. Intracellular expression of MICA in activated CD4 T lymphocytes and protection from NK cell-mediated MICA-dependent cytotoxicity. Hum Immunol 2006; 67: 170-82.
45. Fuertes MB, Girart MV, Molinero LL et al. Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. J Immunol 2008; 180: 4606-14.
46. Kajanne R, Miettinen P, Mehlem A et al. EGF-R regulates MMP function in fibroblasts through MAPK and AP-1 pathways. J Cell Physiol 2007; 212: 489-97.
47. Paroo Z, Ye X, Chen S et al. Phosphorylation of the human microRNA-generating complex mediates MAPK/Erk signaling. Cell 2009; 139: 112-22.
48. Tang KF, Ren H, Cao J et al. Decreased dicer expression elicits DNA damage and up-regulation of MICA and MICB. J Cell Biol 2008; 182: 233-9.
49. Li YP, Chen Y, John J et al. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J 2005; 19: 362-70.
50. McClung JM, Judge AR, Powers SK et al. p38 MAPK links oxidative stress to autophagy-related gene expression in cachectic muscle wasting. Am J Physiol Cell Physiol 2010; 298: C542-9.
51. Thomas M, Wills M, Lehner PJ. Natural killer cell evasion by an E3 ubiquitin ligase from Kaposi's sarcoma-associated herpesvirus. Biochem Soc Trans 2008; 36: 459-63.
52. Fan QW, Cheng C, Knight ZA et al. EGFR signals to mTOR through PKC and independently of Akt in glioma. Sci Signal 2009; 2: ra4.
53. Li L, He S, Sun JM et al. Gene regulation by Sp1 and Sp3. Biochem Cell Biol 2004; 82: 460-71.
54. Williams T, Admon A, Luscher B et al. Cloning and expression of AP-2, a cell-type-specific transcription factor that activates inducible enhancer elements. Genes Dev 1988; 2: 1557-69.
55. Imagawa M, Chiu R, Karin M. Transcription factor AP-2 mediates induction by two different signal-transduction pathways: protein kinase C and cAMP. Cell 1987; 51: 251-60.
56. Langmann T, Buechler C, Ries S et al. Transcription factors Sp1 and AP-2 mediate induction of acid sphingomyelinase during monocytic differentiation. J Lipid Res 1999; 40: 870-80.
57. Apetoh L, Ghiringhelli F, Tesniere A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-9.
58. Machiels JP, Reilly RT, Emens LA et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 2001; 61: 3689-97.
59. Borg C, Terme M, Taieb J et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 2004; 114: 379-88.